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Allergic rhinitis (AR) has a major effect on the quality of life. It also affects work performance, sleep, and school attendance [1]. AR is a common in children 
and is one of the most frequent health problems. It is a highly 
prevalent disease in many countries, affecting about 10-20% 
of the general population [2,3]. AR is characterized by 
paroxysms of sneezing, rhinorrhea, and nasal obstruction, often 
accompanied by itching of the eyes, nose, and palate. Cough, 
postnasal drip, irritability are other common symptoms [4,5]. 
According to the time of exposure, it can be subdivided into 
perennial, seasonal, and occupational disease. An occupational 
AR is rare in children. Perennial AR is mostly caused by dust 
mites and animal dander while seasonal AR is mainly related 
to a variety of pollen allergens. It can be also categorized 
as mild intermittent, moderate to severe intermittent, mild 
persistent, and moderate to severe persistent AR as per ARIA 
classification  [6].
There are many modes of the treatment. Among all the 
methods of treatment, every method has its own limitations 
and degree of success. Topical as well as oral antihistamines 
both are recommended as the first-line therapy in the treatment 
of AR [4,7]. Second-generation antihistaminic agents are 
usually preferred because they are causing lesser sedation, 
performance impairment, and other side effects in children [8]. 
Topical antihistamines mainly target nasal symptoms, whereas 
oral antihistamines primarily target symptoms associated 
with histamine release such as sneezing, rhinorrhea, 
itchiness, watering, redness of eyes, and simultaneously oral 
antihistamines have some effect on nasal congestion too but 
less than intranasal agents.
Oral antihistamines are approved for use in young children. 
Desloratadine and cetirizine are approved for use in children 
above 6 months of age. Loratadine and fexofenadine are used in 
children above 2 years of age and levocetrizine above 6 years. 
Although not as fast as topical histaminic, oral antihistamines 
have also a relatively rapid onset of action [9]. Levocetrizine 
works by blocking histamine receptors. It is a non-sedating 
antihistamine, worked by preventing the action of histamines. 
Considering above facts the present study was done with an 
objective of to evaluate the efficacy in the form of symptomatic 
relief, histopathological response and safety of topical and 
systemic antihistaminic drugs in children with AR.
MATERIALS AND METHODS
The study was a prospective study and carried out in the 
Department of Pediatrics, ENT with active collaboration of 
Department of Pathology at a Tertiary Care Teaching Hospital 
of North India. The duration of study was from August 2014 
to July 2015. Ethical clearance was taken from Institutional 
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Ethics Committee. Children from Pediatric and ENT OPD aged 
6 to 18 years with clinical diagnosis of AR were selected for 
study. An informed consent was obtained from parent before 
recruitment in the study. AR was diagnosed clinically by the 
presence of any 2 or more of the following 4 clinical features-
nasal blockage, rhinorrhea, sneezing, and itching for more than 
1 h every day for more than 2 weeks duration [10]. Children, 
who received systemic or topical steroids within 4 weeks, 
or antihistaminic, decongestant drugs within past 7 days, 
were excluded from study. Children with gross anatomical 
abnormality like polyp, chronic sinusitis, deviated nasal 
septum, throat abnormality, and children less than 6 years were 
also excluded from the study. Children with any other systemic 
diseases were also excluded from study.
Selected children were divided into two groups randomly 
using computer generated random number tables. Detailed 
history and clinical examination were done for every child. 
Routine investigations - such as complete blood count, absolute 
eosinophil count, and X-ray paranasal sinuses - were done in 
every case. Group A children received oral second generation 
antihistamine levocetrizine in dose of 5 mg once at night if age 
above 12 years and 2.5 mg at night if age less than 12 years. 
Group B children received intranasal antihistaminic azelastine 
nasal spray one puff in each nostril twice daily. Both group 
received medications for 4 weeks. Specimen from nasal 
mucosa was taken under local anesthesia in all the children 
after completing 4 weeks of treatment.
The post-therapy symptomatic responses were divided into 
three categories, i.e. (1) Good response - complete absence 
of symptoms, (2) Fair response - some relief in symptoms, 
and (3) Poor response - no improvement. Histopathological 
responses were also divided into three categories: (1) Good 
response - normal histopathology, (2) Fair response - some 
improvement, and (3) Poor response - no improvement. Various 
symptomatic and histopathological responses were recorded in 
a three-point Likert scale (poor response, fair response, good 
response). Subsequently, these were tabulated and comparisons 
were made for a difference in the two responses at 95% 
confidence interval using Mann–Whitney test.
RESULTS
A total of 84 children with clinical AR were enrolled in the 
study divided into two groups randomly as shown in Fig. 1. Out 
of 84 children, only 76 children completed the study leaving 
38 children in each group. There was no statistically significant 
difference in baseline characteristics of recruited subjects 
like age, sex, weight, socio-economic status, and severity of 
symptoms between two groups. The Group A children received 
oral levocetrizine and Group B children azelastine nasal spray. 
There were 24 males and 14 females in Group A and 23 males 
and 15 females in Group B.
Table 1 shows that better symptomatic response in sneezing 
and rhinorrhea was observed in the Group A (levocetrizine 
group) in comparison to Group B (azelastine group) children. 
This difference was statistically significant (p=0.009 and 
p=0.023 respectively). However, a better response in “nasal 
obstruction” was observed with the azelastine (Group B) 
than levocetrizine (Group A). The difference was statistically 
significant (p=0.002). An more number of subjects reported 
good response to itching of the nose in the levocetrizine group, 
while more number of subjects in azelastine group reported 
fair response to nasal itching; this difference was, however, not 
statistically significant (p=0.124).
Table 2 shows the difference in histopathological response 
between two groups. Most of the children in both groups 
showed fair histopathological response (p>0.992) indicating 
no significant difference in histopathological response in both 
the groups. Side effects - such as dryness of mouth and nose, 
altered taste, nasal burning, sleepiness, headache, and visual 
problems - were monitored and none of the patients from both 
groups showed any serious effect that warrant termination of 
the treatment.
DISCUSSION
In this study, male predominance may be due to the fact that most 
of the children were from rural background and belonged to 
low socio-economic status and low education level or illiterate 
families who were giving more care to male than the female 
Figure 1: Flow chart of study
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children. Another probable cause for male predominance may 
be increased outdoor exposures and hence, allergens in males 
than females especially in adolescents. Chanda et al. [11] also 
reported male predominance in their study.
In our study, there was better response of levocetrizine for 
sneezing and rhinorrhea as compared to local azelastine but 
poor response for nasal blockage by levocetrizine in comparison 
to azelastine. Srivastava et al. [12] reported that azelastine is 
showing better result than levocetrizine in all the symptoms 
(sneezing, nasal obstruction and rhinorrhea) in adults probably 
because of better compliance of topical medications in adults 
than in children.
In our study, histopathalogical improvement after 
completing 4 weeks of treatment with systemic levocetrizine 
and topical azelastine were similar and statistically no 
significant difference were found. Shrivastava et al. [12] also 
reported similar findings in their study.
Our children were complaining irritability with azelastine 
and were more comfortable with systemic levocetrizine. 
The response on nasal itching was almost similar in both the 
groups and having no statistical significant difference in both 
levocetrizine and azelastine groups.
Sastre and Mosges [13] did their study to know the safety 
of local and systemic medications in adults and found that local 
medications were having better safety than systemic medications 
with similar efficacy. We also found almost similar efficacy of 
local and systemic medications for symptomatic response, but 
systemic medications were having more acceptability than local 
intranasal medications especially in children. Study limitations 
were short duration of study, small sample size, difficulty to do 
biopsy in children.
CONCLUSION
Allergic rhinitis is children are more common in adolescent 
age group with male predominance. The common symptoms 
were sneezing and rhinorrhea. Levoctrizine showed better 
symptomatic response as compared to topical azelastine 
for sneezing and rhinorrhea and inferior response for nasal 
obstruction in children. Histopathological responses were 
similar in both levocetrizine and azelastine groups.
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